J.C.R). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Transient, repetitive occlusion stimulates coronary collateral growth (CCG) in normal animals. Vascular smooth muscle cells (VSMCs) switch to synthetic phenotype early in CCG, then return to contractile phenotype. CCG is impaired in the metabolic syndrome. We determined whether impaired CCG was attributable to aberrant VSMC phenotypic modulation by miR-145-mediated mechanisms, and whether restoration of physiological miR-145 levels in metabolic syndrome (JCR rat) improved CCG. Approach and Results-CCG was stimulated by transient, repetitive left anterior descending artery occlusion and evaluated after 9 days by coronary blood flow measurements (microspheres). miR-145 was delivered to JCR VSMCs via adenoviral vector (miR-145-Adv). In JCR rats, miR-145 was decreased late in CCG (≈2-fold day 6; ≈4-fold day 9 versus SD), which correlated with decreased expression of smooth muscle-specific contractile proteins (≈5-fold day 6; ≈10-fold day 9 versus SD), indicative of VSMCs' failure to return to the contractile phenotype late in CCG. miR-145 expression in JCR rats (miR-145-Adv) on days 6 to 9 of CCG completely restored VSMCs contractile phenotype and CCG (collateral/normal zone flow ratio was 0.93±0.09 JCR+miR-145-Adv versus 0.12±0.02 JCR versus 0.87±0.02 SD). Conclusions-Restoration of VSMC contractile phenotype through miR-145 delivery is a highly promising intervention for restoration of CCG in the metabolic syndrome. (Arterioscler Thromb Vasc Biol. 2013;33:727-736.)
T ransient repetitive coronary artery occlusion, characteristic of stable angina, and resultant myocardial ischemia (RI) stimulate coronary collateral growth (CCG) in healthy humans and normal animals. [1] [2] [3] [4] Clinically, patients with stable angina have decreased incidence of fatal myocardial infarction, which is associated with better developed collateral networks. 1 However, CCG is severely impaired in metabolic syndrome patients [5] [6] [7] [8] and in our metabolic syndrome rat model (JCR:LA-cp or JCR). 3, 9 In the healthy canine model, CCG has been documented to progress through distinct stages. The early stage begins with endothelial activation and accumulation of bone marrowderived progenitor and inflammatory cells. This is followed by degradation of the basement membrane, vascular smooth muscle cells (VSMCs) phenotype switch from the adult, quiescent, contractile phenotype to the synthetic, proliferative and migratory phenotype, and proliferation and migration of endothelial cells and VSMCs into the lumen of the preexisting native collateral vessel. The later phase is characterized by outward endothelial cell and VSMC migration, luminal expansion, and the VSMCs' return to the contractile phenotype. 10 Thus, the transient switch of the VSMCs to the synthetic phenotype early in the process and their return to the contractile phenotype late in the process seem to be an important component of normal CCG.
However, VSMC phenotype has never been investigated during collateral development in the metabolic syndrome. The coronary vasculature of metabolic syndrome patients and JCR rats is characterized by neointimal lesions even very early in progression of coronary disease. In JCR rats, these lesions consist primarily of proliferative, synthetic VSMCs, and some macrophages. 11 Consequently, we hypothesized that aberrant VSMC phenotype regulation, specifically, the inability of the VSMCs to assume the contractile phenotype played a causative role in impaired CCG in the metabolic syndrome.
VSMC phenotype is predominantly regulated by the competitive binding of serum response factor (SRF), coactivator, myocardin, and repressors, Krueppel-like factor 4 (KLF4) and phosphorylated Elk-1 (p-Elk-1), to the CArG box in the promoter of the smooth muscle (SM)-specific genes. If myocardin is bound to SRF, SRF binds to the CArG box resulting in the transcription of the SM-specific genes, including the SM-specific contractile proteins, SM-myosin heavy chain (SM-MHC), SM-α-actin, calponin and caldesmin, and the contractile VSMC phenotype. If, however, KLF4 expression is increased, it displaces SRF, even if bound by myocardin, from the CArG box, and the SM-specific genes will not be transcribed, resulting in the synthetic VSMC phenotype. p-Elk-1 displaces myocardin from SRF; thus, an increase in its abundance also results in the synthetic VSMC phenotype. 12 Over the last several years, it has been shown that the major negative regulators of Elk-1 and KLF4 abundance are microR-NAs (miRs)-143 and -145, respectively. 13 miR-145 directly targets KLF4 and downregulates its expression, thus enabling SRF binding to the CArG box, whereas miR-143 downregulates Elk-1. 13 miR-145 also indirectly upregulates myocardin. 13 miR-143 and -145 are highly enriched in VSMCs with negligible expression in other cell types. 14 Not surprisingly, they have emerged as the major regulators of VSMC phenotype. 13 miR-145 was sufficient to stimulate multipotent neural crest cells differentiation in VSMCs. 15 Correlating with neointimal lesions marked by synthetic VSMCs, miR-145 was significantly reduced in patients with coronary artery disease. 16 Similarly, our preliminary data showed downregulation of miR-145 in VSMCs in JCR rats. However, nothing is known about the possible involvement of miRs in the regulation of collateral development. Therefore, in the present study, we sought to determine whether restoring physiological miR-145 levels would restore the contractile VSMC phenotype and whether this would be sufficient to restore CCG in the metabolic syndrome.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Previous data from our laboratory demonstrate that RI induces maximal CCG in the normal (Sprague-Dawley [SD]) rats but does not stimulate CCG in metabolic syndrome (JCR) rats. 3 Nine days of RI stimulate maximal CCG in the SD rats. Prolonging the duration of RI to 14, 21, or 28 days does not induce CCG in the JCR rats ( Figure I in the online-only Data Supplement).
VSMCs Adopt the Contractile Phenotype in the Later Stages of CCG in Normal but Not in the Metabolic Syndrome Animals
VSMC contractile phenotype was evaluated by measurements of SM-specific contractile protein expression using SM-specific antibodies ( Figure 1A ). SM-MHC, expressed exclusively by contractile smooth muscle, decreased in the CZ on day 3 of RI in both rat phenotypes (≈75% versus day 0 RI), indicating a switch to a less contractile phenotype. However, in the later stages of CCG, although SM-MHC expression gradually and dramatically increased (5.5±0.5-fold on day 6 RI; 10.1±0.4-fold on day 9 RI) in the CZ of normal (SD) rats, no increase in SM-MHC expression was observed in the CZ of metabolic syndrome (JCR) rats (0.3±0.6-fold on day 6 RI; 1.2±0.6-fold on day 9 RI) ( Figure 1B ). Baseline SM-MHC expression was also ≈1.5-fold higher in SD than in JCR rats. SM-α-actin followed a similar expression pattern, although its expression did increase almost 2-fold in the CZ of some JCR animals on day 9 of RI ( Figure 1B ). This increase was, however, not statistically significant and was confined to the lumen of immature collaterals that failed to undergo expansion ( Figure 1A ) and is likely attributable to the fact that although SM-α-actin is expressed predominantly by contractile smooth muscle, it can be expressed by other cell types relevant to the process of collateral remodeling, including synthetic VSMCs, macrophages, and myeloid progenitor cells. 17 No change in SM-MHC or SM-α-actin expression was observed during the course of CCG in the NZ ( Figure II in the online-only Data Supplement). Expression of nonmuscle myosin (NMHC-B), a marker of synthetic VSMC phenotype, inversely correlated with SM-MHC expression in both rat phenotypes ( Figure 1B) .
Because myocardin and KLF4 are major regulators (myocardin-positive; KLF4-negative) of SM-specific contractile protein expression and targets of miR-145, we next evaluated their expression along the time course of CCG in the 2 rat models. Basal myocardin expression was ≈1.5-fold higher in SD versus JCR rats correlating with SM-specific contractile protein expression. Myocardin decreased in both SD and JCR rats on day 3 of RI (≈30% versus day 0 RI), then increased on days 6 (2.2±0.4 fold) and 9 (2.0±0.2 fold) of RI in SD, but not in JCR rats ( Figure 1C ). Correlating with increased basal SM-MHC and SM-α-actin expression, basal KLF4 expression was ≈2-fold higher in JCR versus SD rats and increased on day 3 of RI in both rat phenotypes (1.9±0.1-fold in SD; 2±0.05-fold in JCR) correlating with the decrease in SM-MHC and SM-αactin expression, then returned to baseline on days 6 and 9 of RI (1±0.2-fold) in SD, but not in JCR (2.8±0.15-fold on day 6 RI; 3.3±0.2-fold on day 9 RI) rats ( Figure 1C ). Thus, the temporal expression of both myocardin and KLF4 correlated with the return of the SD but not JCR VSMCs to the contractile phenotype in the later stages of coronary collateral remodeling. No change in protein expression was observed during the course of CCG in the NZ ( Figure II in the online-only Data Supplement).
In the aggregate, these data indicate a switch to less contractile, more synthetic VSMC phenotype in the early phase of CCG in both phenotypes. However, although in the normal phenotype the VSMCs return to the normal, adult contractile phenotype in the later stages of CCG, this does not occur in the metabolic syndrome phenotype. This aberrant VSMC phenotype switching correlates with the failure of native collaterals to enlarge in the metabolic syndrome phenotype as evident by the difference in collateral diameter between SD and JCR rats shown in Figure 1A and Figure VIII in the onlineonly Data Supplement, which is representative of the average collateral diameter in the 2 rat phenotypes (quantified in Figure  4B ). Immunohistochemistry analysis in Figure VI in the onlineonly Data Supplement illustrates the connection between abundant SM-specific contractile protein expression and collateral expansion (growth) in normal (SD) animals versus low level of SM-specific contractile protein and high level of synthetic marker expression and failure to undergo collateral expansion (growth) in the metabolic syndrome (JCR) animals.
MicroRNA-145 Is Decreased in the Later Stages of CCG in the Metabolic Syndrome Animals
Although only miR-145 has been shown to directly downregulate KLF4 expression and upregulate myocardin available for Bottom: Representative Western blots in the CZ using anti-SM-MHC and anti-SM-α-actin and in the CZ and NZ using anti-NMHC-β antibodies. β-tubulin is the loading control. C, Same as B except that antimyocardin (left) and anti-Krueppel-like factor 4 (anti-KLF4; right) antibodies were used, n=7. β-tubulin is the loading control.
SRF binding, 13 both miR-143 and miR-145 have been shown to regulate VSMC phenotype. 13 Therefore, we examined both miR-143 and miR-145 expression during CCG in normal versus metabolic syndrome rats. There was no difference in basal miR-143 expression between SD and JCR rats, and RI did not change miR-143 expression in either rat phenotype. In contrast, baseline miR-145 levels were ≈30% lower in JCR versus SD rats. miR-145 decreased to a similar level (≈50% versus day 0 RI) in both rat phenotypes on day 3 RI. However, in the SD rats, miR-145 levels then increased back toward baseline in the later stages of CCG, reaching baseline on day 6 and increasing nearly 2-fold on day 9 of RI. In contrast, in the JCR rats, miR-145 levels remained decreased (≈50% versus day 0 RI on days 6 and 9 RI) ( Figure 2A ).
Our in situ hybridization studies show VSMC-specific miR-145 expression as expected. In addition, we consistently demonstrate both stronger intensity of staining and larger numbers of miR-145-positive cells in SD rats on day 9 of RI ( Figures  2B and 3A) . These results suggest that the observed increase in miR-145 levels on day 9 of RI, versus baseline, in the SD rats is a consequence of a greater total number of contractile VSMCs consistent with collateral vessel enlargement and concomitant medial thickening. In contrast, decreased miR-145 levels in JCR rats on day 9 of RI, versus baseline, are a consequence of both decreased miR-145 expression within individual cells in JCR rats, suggestive of an RI-induced individual VSMC switch toward a less contractile phenotype, which could be a causative factor in lack of collateral expansion, and lack of medial thickening as a consequence of lack of collateral expansion.
MicroRNA-145 Delivery Restores VSMC Contractile Phenotype in the Later Stages of CCG in the Metabolic Syndrome
MicroRNA-145 was delivered via an Adv vector (miR-145-Adv). VSMC-specific expression was ensured by placing the miR-145 sequence under the direction of an SM-specific SM22a promoter and confirmed by in situ hybridization ( Figure 3A ). The amount of miR-145-Adv delivered was adjusted until there was no significant difference between miR-145 levels expressed in treated JCR rats and untreated SD rats (0.34±0.03 JCR RI+miR-145-Adv versus 0.31±0.03 SD RI pg miR-145/200 ng total RNA) ( Figure 3A ). miR-145-Adv specificity was confirmed by the fact that it did not alter expression of other cardiac-or vascular-enriched miRs, including miR-21 and miR-143 ( Figure II in the online-only Data Supplement).
Because myocardin and KLF4 are targets of miR-145, we assessed the effect of miR-145-Adv delivery on their expression. Restoration of miR-145 levels in JCR rats to those found in the SD rats on day 9 of RI by miR-145-Adv delivery restored both myocardin (≈2-fold increase versus NZ for JCR RI+miR-145-Adv and SD RI versus ≈1-fold for JCR RI) and KLF4 (≈1-fold increase versus NZ for JCR RI+miR-145-Adv and SD RI versus ≈3-fold for JCR RI) expression in the CZ of JCR rats to those found in the SD rats ( Figure 3B ). Although KLF5 is a known regulator of smooth muscle phenotype and a known target of miR-145, miR-145-Adv did not effect KLF5 expression. KLF5 expression was also not changed in response to RI in either SD or JCR rats ( Figure VII in the online-only Data Supplement).
Importantly, SM-MHC and SM-α-actin expression on day 9 of RI in the CZ of miR-145-Adv-treated JCR rats equaled that in the untreated SD rats (≈10-fold increase versus NZ for JCR RI+miR-145-Adv and SD RI versus ≈1-fold for JCR RI; Figure 3C ), indicating that the expression of physiological miR-145 levels was sufficient to restore the VSMC contractile phenotype in the later stages of CCG in the metabolic syndrome.
miR-145-Adv also significantly increased SM-MHC and SM-α-actin expression in the NZ of JCR rats (≈4-and ≈3-fold, respectively; Figure 3C ). Similarly, miR-145-Adv increased myocardin and decreased KLF4 expression ≈1.5-fold in the NZ of JCR rats ( Figure 3B ). The effects in the NZ were likely lesser in magnitude than in the CZ because transduction efficiency in the NZ was lesser than in the CZ (≈90% of VSMCs in the CZ versus 40% of VSMCs in the NZ; Figure III in the online-only Data Supplement) because of our method of Adv delivery, which apparently favors retention of the construct in the CZ over the NZ. Enhanced green fluorescent protein-Adv delivered to a separate group of SD and JCR rats, at the same concentration and on the same day of RI because the miR-145-Adv had no effect on SM-specific contractile protein, KLF4, or myocardin expression in the CZ or the NZ, indicating that the observed effects were miR-145 specific ( Figure 3B and 3C) . Angiotensin-converting enzyme (ACE) is another relevant verified target of miR-145. 18 To determine whether ACE downregulation was responsible for the beneficial effects of miR-145 delivery on CCG in the JCR rats, we examined the effects of miR-145-Adv on ACE expression. miR-145-Adv did not effect ACE expression in either SD or JCR rats. Moreover, ACE expression was not different between the 2 rat phenotypes and did not change in response to RI ( Figure  IV in the online-only Data Supplement). The beneficial effect of miR-145 on CCG was also not attributable to the amelioration of the metabolic syndrome because miR-145-Adv had no effect on weight, plasma insulin, glucose, triglycerides, highdensity lipoprotein, low-density lipoprotein, or blood pressure in JCR rats.
MicroRNA-145 Delivery Completely Restores CCG in the Metabolic Syndrome
Finally, we investigated the effects of miR-145-Adv on CCG in the metabolic syndrome. Myocardial blood flow in the CZ and the NZ was measured in the same rats in which the physiological amount of miR-145 (equal to that seen in SD rats on day 9 of RI) delivered via the miR-145-Adv was shown to restore the VSMC contractile phenotype in Figure   SD 3. On day 9 of RI, mean CZ flow was 2.1±0.05 mL/min per g in miR-145-Adv-treated JCR rats versus 0.15±0.03 mL/ min per g in untreated JCR rats and 1.89±0.08 mL/min per g in untreated SD rats. Collateral/normal zone flow ratio was 0.93±0.09 (JCR RI+miR-145-Adv), 0.12±0.02 (JCR RI), and 0.87±0.02 (SD RI; Figure 4C ). This complete restoration of normal blood flow was coupled to increased arteriolar density, which equaled that observed in the normal (SD) rat in response to RI (2.8±0.5 versus 2.6±0.6). Capillary density showed a tendency to increase significantly in some JCR animals (2 of 7) treated with the miR-145-Adv, but there was no overall significant increase in capillary density ( Figure 4A ). RI alone likewise had no effect on capillary density in JCR rats but caused a significant increase in capillary density in SD rats (≈1.8-fold versus baseline). Because wall thickness was comparable between groups on day 9 RI, measurements of wall thickness to lumen diameter ratios in Figure  4B further confirm the significant increase in arteries with expanded lumen in response to miR-145 delivery in JCR rats (wall thickness/lumen diameter was ≈4 for JCR RI versus ≈0.25 for JCR RI+miR-145-Adv and SD RI). Because of the anatomy of the coronary vasculature in rats, it is not possible to isolate collateral arteries; therefore, we used the fact that only actively remodeling vessels in the heart would contain proliferating cells to distinguish collaterals from the preexisting, nonremodeling vasculature. Thus, only coronary arteries, which also stained positive for the proliferating nuclear antigen ( Figure 4B ), were used for these measurements.
Taken together, these results indicate that restoration of physiological miR-145 levels in the later stages of CCG in the metabolic syndrome was sufficient to completely restore blood flow and that CCG, and not angiogenesis, is the major mechanism by which this occurred. In contrast, delivery of miR-145-Adv to normal (SD) animals to overexpress miR-145 significantly decreased CCG ( Figure 5A ). Delivery of anti-miR-145 to downregulate native miR-145 levels likewise blocked CCG in normal animals ( Figure 5B ). Overexpression of miR-145 and complete inhibition of native miR-145 expression by antimiR-145 was confirmed by real-time polymerase chain reaction ( Figure 5A and 5B ). Enhanced green fluorescent protein-Adv delivered to a separate group of SD and JCR rats, at the same concentration and on the same day of RI as the miR-145-Adv, had no effect on CCG ( Figures 4A,  4B, 4C, and 5A) . Similarly, scrambled antimiR, which did not lower native miR-145 levels, had no effect on CCG ( Figure  5B) . These results indicate that the observed effects on CCG were miR-145 specific.
Discussion
The most important novel findings of our study are as follows: (1) miR-145 expression is decreased at baseline and in the later stages of CCG in the coronary VSMCs of metabolic syndrome animals which correlates with failure of the VSMCs to assume the contractile phenotype and impaired CCG; and (2) restoration of physiological miR-145 expression in the metabolic syndrome enables the VSMCs to assume the contractile phenotype in the later stages of collateral remodeling and completely restores CCG. Our data further demonstrate that the normal physiological level of miR-145 is essential for collateral remodeling. Downregulation of miR-145 in normal animals inhibited CCG. However, although physiological miR-145 amounts completely restored CCG in the metabolic syndrome animals, overexpression of miR-145 severely compromised CCG in normal animals. Greater than physiological levels of miR-145 also induced a hypercontractile and hypertrophied phenotype in VSMCs in pulmonary artery hypertension. Reduction of miR-145 levels by antimiR-145 restored normal VSMC phenotype and reduced pulmonary artery pressure and pulmonary artery hypertension symptoms. 19 Taken together, these observations emphasize the importance of physiological levels of miR-145 for normal vascular structure and function.
Another interesting aspect of our study is that our data convincingly demonstrate that RI alters miR-145, but not miR-143 expression, in both the normal and the metabolic rat models of CCG. miRs-143/-145 are transcribed as a bicistronic unit with common regulatory elements and are typically upregulated or downregulated together. 13 However, miR-143 and miR-145 target different downstream effectors. Although miR-145 targets myocardin, KLF4, and KLF5, miR-143 targets Elk-1. 13 Importantly, upregulation of miR-145 was sufficient to induce expression of SM-specific marker genes, and its inhibition was sufficient to downregulate expression of these markers. 15 miR-145 alone has been shown to be sufficient to stimulate multipotent neural crest cells differentiation into VSMCs. 15 These data indicate that miR-145 may be the primary regulator of VSMC phenotype in adult VSMCs. Our results demonstrate that the miR-143/-145 cluster is differentially regulated in CCG and that downregulation of miR-145, but not miR-143, underlies impaired CCG in the metabolic syndrome.
miR-145 is also the most abundant miR in normal, healthy arterial walls, and VSMCs and has been shown to be the major determinant of VSMC phenotype in vivo. 13 Restoration of miR-145 expression limited neointima formation in response to vascular injury by promoting KLF4 downregulation and VSMC contractile protein expression. 14, 15 This is particularly relevant with respect to our results, which show an increase in miR-145 in normal (SD) rats, but not in the metabolic syndrome (JCR) rats, in the later stages of CCG when the neointima resolves and luminal expansion occurs in the normal, but not the metabolic syndrome, phenotype. miR-145 has also been shown to be able to suppress cell proliferation in many human cancers. [20] [21] [22] However, its antiproliferative effects in VSMCs seem to be mediated by restoration of the contractile VSMC phenotype. KLF4 also targets many genes that regulate VSMC proliferation and migration. Therefore, because KLF4 binding to the CArG box and subsequent inhibition of SM-specific gene transcription is regulated by its relative abundance, high expression of the SM-specific genes is most often associated with low VSMC proliferation and migration rates, whereas low expression of SM-specific genes is most often associated with high proliferation and migration rates. 23 miR-145 did not effect KLF5 expression in our study, nor did KLF5 change in response to RI, suggesting that in contrast to KLF4, KLF5 does not play a role in VSMC phenotype regulation during CCG. Other studies have reported differential regulation of KLF4 and KLF5.
For example, KLF4 expression was increased in response to oxidative stress in neonatal myocytes, whereas KLF5 was unchanged. 24 A single study explored VSMC phenotype switching during CCG in normal dogs and correlated the synthetic, proliferative phenotype with the early phase and the contractile phenotype with the late phase of CCG. 25 However, a definitive causeconsequence relationship between VSMC phenotypic switching and collateral development has not been established. In contrast to upregulating medial thickness via VSMC hypertrophy, miR-145 has been shown to limit intimal thickening by decreasing neointimal formation in response to angioplastytype vascular injury through promoting VSMC phenotype switching from synthetic to contractile. 15 In our study, delivery of miR-145 at the transition from inward to outward remodeling likewise improves CCG in the metabolic syndrome by facilitating synthetic to contractile VSMC phenotype switching and resolution of the neointima, suggesting universal consequences of physiological levels of miR-145 expression in the vasculature.
Very recently, ACE was verified as a target of miR-145. 18 The significance of this regulation in vivo was unknown. Our previous studies have shown that angiotensin II type 1 receptor inhibition and inhibition of angiotensin II type 1 receptordependent reactive oxygen species production was beneficial for CCG in the metabolic syndrome. 3 However, our current results demonstrate that the beneficial effects of miR-145 are independent of ACE downregulation, and therefore likely, of angiotensin II-mediated signaling.
Our study does not definitively prove that the capacity of VSMCs to assume the contractile phenotype in the later stages of collateral remodeling fully accounts for the ability of physiological miR-145 levels to restore CCG in the metabolic syndrome. However, the ability to switch from the synthetic to the contractile VSMC phenotype dictates important functions of the vascular wall in addition to the structural integrity of the tunica media itself. First, as already mentioned, contractile VSMCs also assume low-proliferation rates, which may aid in the clearance of the neointima and luminal expansion. Second, contractile versus synthetic VSMCs produce different extracellular matrix components and proteases, including matrix metalloproteinases, some of which play critical roles in the bioavailability and balance of proangiogenic growth factors and antiangiogenic peptides (growth inhibitors), as well as endothelial cell adhesion and survival. Thus, it is feasible that converting the VSMCs to the physiological, contractile phenotype overcomes a plethora of impediments to successful collateral development, which are present in the metabolic syndrome, including documented endothelial dysfunction, endothelial progenitor cell (EPC) dysfunction, and the altered growth factor/growth inhibitor balance. On the contrary, endothelial dysfunction, a hallmark of metabolic syndrome in humans and animals models including the JCR rat, 26 could be the cause of decreased miR-145 levels and consequent propensity toward the synthetic VSMC phenotype. A recent cell culture study has shown that miRs-143 and -145 were in fact released from endothelial cells to regulate SM-specific gene expression in VSMCs. 27 Figure 5 . A, SD rats were treated with miR-145-adenoviral vector (Adv) or enhanced green fluorescent protein (EGFP)-Adv on day 4 of resultant myocardial ischemia (RI) where indicated, and underwent 9 days of RI, n=7. Left: miR-145 levels determined by real time-polymerase chain reaction. Levels in the CZ are shown. Right: Coronary blood flow was measured in the CZ and the NZ using microspheres during left anterior descending artery occlusion and is expressed as the ratio of collateral/normal zone (CZ/NZ) flows on day 9 of RI. B, Same as A except that rats were treated with anti-miR-145 or scrambled antimiR on day 6 of RI where indicated.
Another limitation of our study is that we did not evaluate the effect of miR-145 delivery on CCG under conditions of maximal vasodilation. We have previously shown that adenosine had no effect on coronary blood flow in the JCR animals, thus demonstrating that any increase in collateraldependent blood flow in response to RI coupled with antioxidant treatment and angiotensin type I receptor blockade was attributable to CCG. 28, 29 However, because miR-145 delivery specifically increases SM-specific protein expression which could increase VSMC contractility, we cannot exclude the possibility that altered vasoactive properties of the coronary vasculature could not affect collateral-dependent blood flow in this study.
Nothing is known about the possible involvement of miRs in the regulation of collateral development. This is the first study to demonstrate a definitive and important role not only for miR-145 specifically but also for miRs in general in the regulation of collateral development. Furthermore, the potential for using miRs for the induction of CCG in conditions where it is impaired remains completely unexplored. This study is the first to demonstrate the feasibility of such an approach. Long-term patency of bypass grafts remains a vexing problem in metabolic syndrome and diabetic patients, with frequent need for revascularization. 30, 31 Thus, the intracardiac route of delivery is specifically applicable during open-heart surgery where stimulation of CCG immediately after coronary bypass grafting (CABG) has been shown to significantly increase the long-term patency of the grafts. Because of previous adverse effects using Adv-mediated delivery in humans, Adv-free delivery would be optimal for effective miR-145based therapy in humans. Such delivery systems are already available for in vivo miR delivery and could be applicable to miR-145 specifically, although with caution, because miR-145 has been shown to be able to convert multiple progenitor cells into VSMCs.
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